Ellevest Inc’s Travere Therapeutics TVTX Stock Holding History

Ellevest Inc’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3	Closed	–	–	1958
2022 Q3	$0	Buy	+3	New	+$78	﹤0.01%	1864

Other funds holding TVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ellevest Inc's TVTX Position: Q4 2022 in Review

Ellevest Inc sold out of Travere Therapeutics (TVTX) in Q4 2022, closing a stake of 3 shares.

Ellevest Inc first reported a position in TVTX in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 155 funds tracked by Wall St. Rank hold TVTX as of Q4 2022.

Ellevest Inc reported no remaining Travere Therapeutics position as of Q4 2022 after selling out during the quarter.
Ellevest Inc sold 3 Travere Therapeutics shares in Q4 2022.
Ellevest Inc first reported a position in Travere Therapeutics in Q3 2022 and held it in 1 quarter.
Ellevest Inc's Travere Therapeutics position peaked at $0 in Q3 2022.
155 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2022.

Based on Ellevest Inc's 13F filing for Q4 2022, filed 3 Feb 2023.